DHAI vs LFMD vs HIMS vs MBOT vs TDOC

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -8. 7% for LifeMD, Inc. (LFMD). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 55. 4x trailing P/E (58. 3x forward), making it the more compelling value choice. Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +173. 9%, compared to -99. 9% for DIH Holding US, Inc. (DHAI). Over 10 years, the gap is even starker: LFMD returned +241. 4% versus DHAI's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DIH Holding US, Inc.

(DHAI) is the lower-risk stock at -1. 21β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately -305% more volatile than DHAI relative to the S&P 500. On balance sheet safety, Microbot Medical Inc. (MBOT) carries a lower debt/equity ratio of 3% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -8. 7% for LifeMD, Inc. (LFMD). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -13. 8% for DIH Holding US, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -10. 4% for TDOC. At the gross margin level — before operating expenses — LFMD leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MBOT: 158.

2% to $5. 50.

In this comparison, LFMD (1.

4% yield) pays a dividend. DHAI, HIMS, MBOT, TDOC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DIH Holding US, Inc.

(DHAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1. 21)). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DHAI: -99. 9%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DHAI is a small-cap quality compounder stock; LFMD is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; MBOT is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. LFMD pays a dividend while DHAI, HIMS, MBOT, TDOC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.